Navigation Links
Putney, Inc. Enters the $175M Annual Veterinary NSAID Market
Date:6/23/2009

Makes Treatment More Affordable to Pet Owners

PORTLAND, Maine, June 23 /PRNewswire/ -- Putney, Inc., a pharmaceutical company focused on the development of generic drugs for pets, has launched carprofen caplets, a bioequivalent generic version of the canine medication Rimadyl(R) caplets. Putney's carprofen is offered so as to cost at least 25% less to veterinarians than its branded competitor -- allowing veterinarians to provide savings for pet owners and increasing profits to veterinary practices in this tough economy.

Carprofen is widely used in dogs for the relief of pain and inflammation associated with osteoarthritis, as well as the control of post-operative pain associated with soft tissue and orthopedic surgeries. In a recent survey conducted by Advanstar Veterinary Healthcare Communications, 96% of responding veterinarians nationwide indicated they prescribe and dispense branded carprofen medications. Putney's carprofen caplets have demonstrated bioequivalence to Pfizer's Rimadyl(R) caplets in an FDA approved study and will be available in the same strengths (25mg, 75mg and 100mg caplets) and convenient packaging as the branded drug.

In the Advanstar survey, 80% of companion animal veterinarians surveyed across the country responded that they would feel comfortable switching to generic carprofen caplets and 88% believe that pet owners are receptive to switching to the generic.

In general, in spite of expired patents on many veterinary drugs, few cost-saving generics have been developed and approved by the FDA for pets. "With carprofen caplets, Putney is delivering a high quality, bioequivalent generic option to veterinarians to help pet owners afford to treat pets," said Jean Hoffman, CEO and founder of Putney. Carprofen caplets are the first FDA approved veterinary generic in Putney's pipeline of veterinary generic and specialty drugs. Ms. Hoffman says Putney expects future sales of more than $20 million annually for carprofen products, subject to FDA approval for the Company's generic drug applications for various forms of carprofen. Putney's carprofen caplets are available from selected licensed veterinary distributors such as First Veterinary Supply in Michigan -- and directly from Putney for large veterinary practices.

Putney, Inc., is a pharmaceutical company that listens to companion animal veterinarians and responds to their needs -- making affordable drugs available, and developing products that address common concerns such as compliance, dosing and palatability. Putney empowers veterinarians with prescribing choices that allow them to pursue the best course of treatment for improved compliance, more satisfied pet owners and happy pets. Learn more at www.putneyvet.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=88021


'/>"/>
SOURCE Putney, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Enters Into a $15 Million Revolving Credit Facility
2. Joint Commission President Emeritus Joins Truman Medical Centers Board of Directors
3. VIDEO: Cancer Treatment Centers of America Selects Site in GA for Proposed Hospital Serving Patients in Southeast
4. U-M Hospitals & Health Centers Weathers Tough Economic Climate, Plans for Growth
5. Leading Healthcare Group Selects Varian Medical Systems to Supply Cancer Treatment Technology for Treatment Centers Across the Western United States
6. Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth
7. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
8. VIDEO from Medialink and the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury: Department of Defense Launches New Anti-Stigma Campaign
9. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
10. SETO Holdings, Inc. Completes Agreement to Acquire Advanced Hearing Centers, Inc. and Has Disposed of All Existing Business; New Management has been installed
11. Forterus Inc. Treatment Centers Serving Middle-Class; Rapid Growth Detailed in Paul Howarth Interview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for ... the hiring of Richard Robinson as chief operating officer (COO). In this role, ... a proven track record of simplifying business processes and developing growth strategies to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with ... Angela Cotey, with or without a referral. Dr. Cotey is a trusted dentist who ... preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: